Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CASM regulates lysosomal expansion and cell fate during senescence
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
View: Text | PDF
Research Article Aging Cell biology

CASM regulates lysosomal expansion and cell fate during senescence

  • Text
  • PDF
Abstract

Cellular senescence, a hallmark of aging, is accompanied by a striking expansion of the cell’s lysosomal compartment, yet the pathway leading to increased lysosomal content remains unresolved. Here, we demonstrate that the master lysosomal transcriptional regulator TFEB is activated during senescence through a pathway that involves conjugation of ATG8 onto single membranes (CASM). Using various senescence inducers, we show that senescence induction triggers robust TFEB nuclear translocation and upregulation of TFEB target genes. In contrast, inhibition of the core CASM machinery by CRISPR-mediated deletion of either ATG16L1, ATG12, or ATG5 markedly reduced senescence-induced TFEB nuclear translocation. In ATG16L1-KO cells, reconstitution with WT ATG16L1 but not the CASM-defective ATG16L1F467A mutant restored both ATG8 lipidation on the lysosomal surface and TFEB activation. Moreover, expression of the Salmonella effector protein SopF, a previously described specific CASM inhibitor, similarly blocked senescence-induced TFEB translocation. Functionally, upon stress, CASM-deficient cells exhibited a pronounced shift away from senescence and toward a cell death fate, a phenotype reversed by expressing a constitutively active form of TFEB. Together, these findings identify CASM-dependent TFEB activation as an essential mechanism enabling senescence-associated lysosomal expansion and suggest that lysosomal capacity modulates cell fate decisions in the aftermath of acute stress.

Authors

Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel

×

Figure 2

TFEB activation during senescence occurs independently of canonical mTORC1 signaling and instead requires the CASM machinery.

Options: View larger image (or click on image) Download as PowerPoint
TFEB activation during senescence occurs independently of canonical mTOR...
(A) Immunoblot triplicate analysis of p70 S6 kinase (S6K) and phospho-S6K (p-S6K) in WT BEAS-2B cells on Day 0 (untreated) and Day 3 after senescence induction with 100 nM DOX (dox). (B) Quantification of the p-S6K/S6K ratio. Data are mean ± SD of 3 independent experiments; significance by a ratio paired t test. (C) LysoIP immunoblot of LC3-II from control or senescent (Day 3) BEAS-2B cells expressing TMEM192-3xHA. β-Actin and ATG16L1 serve as loading controls. (D) Immunoblot analysis of LC3 in ATG16L1-, ATG12-, and ATG5-KO BEAS-2B cells ± 200 nM bafilomycin A1 for 24 h; β-actin is loading control. (E) Lyso-IP for WT and ATG16L1-KO cells. Blots are representative of n = 3 independent experiments. (F) Fluorescence imaging of TFEB–EGFP in WT and KO cells on Day 0 and Day 3 after dox. Boxed areas were selected for amplified view (third column). Arrows indicate nuclear TFEB localization. Scale bar: 32 μm. Images are representative of n = 3 independent experiments. (G) Quantification of cells with nuclear TFEB. Mean ± SD from 3 independent experiments (≥30 cells per replicate); statistical significance determined by one-way ANOVA followed by Dunnett’s multiple-comparison test against WT. (H) qPCR of TFEB transcriptional targets, ATP6V1E1 and CTSA, in ATG16L1-KO cells at baseline and Day 1 after dox (+), plotted as fold change (mean ± SD) relative to untreated controls. Statistical significance determined by a 2-tailed unpaired t test with Welch’s correction. See Figure 1D for a similar analysis of WT cells. (I) Immunoblot triplicate analysis of lysosomal LAMP1, cathepsin B, and β-galactosidase in WT or ATG16L1-KO cells on Day 0 and Day 3 after dox. β-Actin is the loading control. ***P < 0.001, ****P < 0.0001; ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts